The nation of Zimbabwe has rejected a substantial US health deal valued at $367m (272 million pounds) over five years because of Washington's demand for confidential information.
This move came to light following a internal memorandum dated December was leaked, indicating that President Emmerson Mnangagwa deemed the deal was "skewed".
An official spokesperson later clarified that the United States was demanding access to genetic material for scientific study and profit but refused to share the benefits from future medical innovations.
"We must now begin the difficult and regrettable task of ending our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had donated more than $1.9bn for health programmes to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for more dialogue to reach a deal agreeable to all parties so the country's vital HIV treatment initiative can proceed.
Wider Context
This rejection comes after a comparable situation in neighbouring Kenya, where a high court blocked a related deal with the US after concerns were raised about the security of Kenyans' health data.
Since returning to office last year, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
USAID had overseen assistance for the US government, but Trump stated its spending was "inefficient" and his government was seeking government-to-government deals to boost openness and responsibility.
According to reports, Sixteen nations in Africa have so far agreed to similar agreements, representing more than $18.3bn in committed funds.
Details of the Declined Agreement
The funds for Zimbabwe was intended to funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this partnership might have yielded significant advantages for Zimbabwean communities, particularly the 1.2 million currently on HIV treatment through US-supported programmes," Tremont added.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"The proposal required Zimbabwe to share its genetic material and health information for a long time, with no equivalent promise of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," Mangwana explained.
"Put simply, our nation would provide the raw materials for medical research without any assurance that the end products would be accessible to our population if a future disease outbreak emerge."
National Interest and Global Health
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were disrupting structures previously established through the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to manage future global health emergencies.
"This framework is intended to guarantee that when a nation contributes its information, the benefits – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
The government's concerns regarding the US deal "are not meant as anti-American sentiment," he added.
"We are open to further dialogue with our US partners on how future co-operation might be designed in a way that respects the sovereignty and interests of each country."
Health Experts Reaction
A leading public health body said it acknowledged the government's concerns, but suggested that talks need to persist given that much of the nation's Aids initiatives depended on international support.
"In cases where specific concerns arise, such as those relating to data governance or agreement terms, these can frequently be resolved through detailed discussion and negotiated safeguards," it said.
This impasse underscores the complex debate between receiving vital foreign assistance and protecting local interests in an ever more data-driven world.